For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BillionToOne (BLLN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
BillionToOne is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BillionToOne is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BLLN's full-year earnings has moved 612.8% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BLLN has returned about 19.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.5% on average. As we can see, BillionToOne is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Eledon Pharmaceuticals, Inc. (ELDN). The stock is up 156.3% year-to-date.
The consensus estimate for Eledon Pharmaceuticals, Inc.'s current year EPS has increased 24.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, BillionToOne belongs to the Medical - Products industry, a group that includes 78 individual companies and currently sits at #170 in the Zacks Industry Rank. This group has lost an average of 24.1% so far this year, so BLLN is performing better in this area.
Eledon Pharmaceuticals, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #146. The industry has moved +0.4% so far this year.
BillionToOne and Eledon Pharmaceuticals, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BillionToOne, Inc. (BLLN): Free Stock Analysis Report
Eledon Pharmaceuticals, Inc. (ELDN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).